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Research Article
Enriched environment enhances b-adrenergic
signaling to prevent microglia inflammation
by amyloid-b
Huixin Xu1 , Molly M Rajsombath1, Pia Weikop2 & Dennis J Selkoe1,*
Abstract
Environmental enrichment (EE) is a rodent behavioral paradigm
that can model the cognitive benefits to humans associated with
intellectual activity and exercise. We recently discovered EE’s anti-
inflammatory protection of brain microglia against soluble oligo-
mers of human amyloid b-protein (oAb). Mechanistically, we report
that the key factor in microglial protection by EE is chronically
enhanced b-adrenergic signaling. Quantifying microglial morphol-
ogy and inflammatory RNA profiles revealed that mice in standard
housing (SH) fed the b-adrenergic agonist isoproterenol experi-
enced similar protection of microglia against oAb-induced
inflammation as did mice in EE. Conversely, mice in EE fed the b-
adrenergic antagonist propranolol lost microglial protection
against oAb. Mice lacking b1/b2-adrenergic receptors showed no
protection of microglia by EE. In SH mice, quantification of nore-
pinephrine in hippocampus and interstitial fluid showed that oAb
disrupted norepinephrine homeostasis, and microglial-specific
analysis of b2-adrenergic receptors indicated a decreased receptor
level. Both features were rescued by EE. Thus, enhanced b-adre-
nergic signaling at the ligand and receptor levels mediates potent
benefits of EE on microglial inflammation induced by human Ab
oligomers in vivo.
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Introduction
The steady aging of the human population and a resultant rise in
the prevalence of Alzheimer’s disease (AD) have made AD among
the most common and feared diagnoses in medicine. Pharmaceuti-
cal approaches have had very limited success to date, and even
when a safe and effective disease-modifying agent is approved, the
cost of its chronic administration and its complex delivery logistics
may still leave many elderly humans underserved. Population stud-
ies increasingly suggest that lifelong experiences such as education,
challenging occupation, exercise, and socialization may all improve
cognitive reserve and provide some protection against the develop-
ment of AD later in life (Nithianantharajah & Hannan, 2009; Then
et al, 2015).
Environmental enrichment (EE) is an animal housing paradigm
aimed at understanding the biological mechanisms that build cogni-
tive reserve (Nithianantharajah & Hannan, 2006; Pang & Hannan,
2013; Hannan, 2014), thereby providing insights for developing
non-pharmaceutical therapeutic approaches to AD. In rodents, EE
has been shown to ameliorate multiple AD-like neuronal pheno-
types, including synaptic loss, impaired synaptic plasticity,
decreased neurogenesis, and altered cognition (Lazarov et al, 2005;
Cracchiolo et al, 2007; Herring et al, 2009; Li et al, 2013). Environ-
mental enrichment provides resistance to neuronal/synaptic toxicity
from exposure to soluble oligomers of amyloid b-protein (oAb), the
most genetically and biologically well-validated pathogenic factor in
AD (Selkoe & Hardy, 2016).
A major feature of AD pathobiology that has barely been studied
with regard to EE is the brain’s innate immune system. Changes in
microglia contribute importantly to the AD phenotype both in
human studies and in animal models (Zhang et al, 2013). Genome-
wide association studies (GWAS) had identified over 20 AD-asso-
ciated gene variants by 2016, and a majority were expressed by
microglia (Villegas-Llerena et al, 2016). We recently showed for the
first time that EE confers extensive anti-inflammatory effects on
microglia in mice examining very early events in oAb toxicity (Xu
et al, 2016). Elucidating the molecular mechanisms by which EE
dampens oAb-induced microglial inflammation could not only
support behavioral approaches but also identify key signaling paths
that might provide new pharmacological targets to slow or prevent
AD.
Norepinephrine (NE) and b-adrenergic signaling are centrally
involved in neuronal activity in cognition and, more recently, in
microglial immune function. NE is released by noradrenergic
neurons that innervate many brain regions, including the dentate
gyrus (DG) where we observed the most robust influences of EE on
microglia (Xu et al, 2016). Although no direct evidence has been
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reported to connect EE with NE in the DG of healthy mice, the NE
system has been found to regulate various features of cognitive
activity (Sara, 2015) that are strongly enhanced by EE. A previous
study from our laboratory found that EE activates b2-adrenergic
receptors (b2-AR) in neuronal synapses as an early part of its neuro-
protective effect against oAb, suggesting links that b2-AR signaling
has with both EE and oAb toxicity (Li et al, 2013). Microglia express
b1- and b2-adrenergic receptors (Mori et al, 2002; Tanaka et al,
2002), and their activation by exogenous agonists causes changes in
microglia morphology and suppression of the pro-inflammatory
cascade induced by lipopolysaccharide stimulation (Hetier et al,
1991; Dello Russo et al, 2004; Markus et al, 2010; Qian et al, 2011).
Furthermore, NE was shown to suppress microglial inflammation
and increase phagocytosis of synthetic Ab42 fibrils in cell culture,
while NE deficiency in APP transgenic mice enhanced brain tissue
cytokine levels and exacerbated AD-like cytopathology (Heneka
et al, 2002, 2006, 2010; Kalinin et al, 2007; Kong et al, 2010).
Here, we report multiple lines of evidence that b-adrenergic
signaling drives the anti-inflammatory benefits of EE on microglia
early in the in vivo response to oAb isolated directly from human
(AD) brain. By combining selective housing with neuropharmaco-
logical treatments, we first show that a b-adrenergic receptor
agonist mimics EE’s anti-inflammatory effects in wild-type mice
housed in standard cages (SH) and exposed to intracerebroventric-
ular (i.c.v) microinjections of human oAb. Conversely, an antago-
nist to b-adrenergic receptors largely blocks such benefits of EE.
Mice with germline knockouts of both b1- and b2-AR also lost
EE’s anti-inflammatory protection of microglia, in accord with the
mice fed propranolol. Further, we find that, in SH mice, oAb
significantly increases norepinephrine level in the dentate gyrus
and decreases it in brain interstitial fluid, and it downregulates
microglial b1/b2AR levels. We conclude that environmental
enrichment upregulates hippocampal b-adrenergic signaling to
provide robust protection of microglia against the inflammatory
effects of human oAb oligomers.
Results
Prolonged oral administration of isoproterenol to SH mice
prevents human oAb-induced microglia inflammation in vivo,
mimicking the protection by EE
Microglia express significant levels of b1/b2AR, suggesting these
receptors have functional roles in microglial biology. To examine
the mechanism underlying EE’s strongly protective effect against the
in vivo microglial reaction to oAb that we recently reported (Xu
et al, 2016), namely EE significantly rescues microglial morphologi-
cal changes and inflammatory RNA profile shifts induced by expo-
sure to oAb, we asked whether prolonged activation of b1/b2AR
signaling could mimic the immunomodulatory effects of EE on
microglia. To achieve constant in vivo stimulation of b1/b2AR with-
out causing stress to the animals, we administered isoproterenol, a
non-selective b1/b2AR agonist, to 4-weeks SH mice continuously in
their daily drinking water (0.1 g/l) for 4–6 weeks, the same period
we have used for EE exposure. The compound is tasteless, and non-
transparent water bottles were used for isoproterenol solution and
plain water. No difference in water consumption was observed
between SH mice on isoproterenol and on plain water, although the
exact amount of water consumed by individual mouse was untrace-
able which may contribute to some variations among mice of the
same treatment group. Also, no significant differences in activity
level and body weight were observed.
We first analyzed microglia morphology in SH mice fed isopro-
terenol or not and then microinjected i.c.v with oAb-rich soluble
cortical extracts (ADTBS) prepared from clinically and neuropatho-
logically typical AD patients (Shankar et al, 2008). TBS extracts
prepared identically from age-matched normal human cortex lack-
ing oAb (Fig EV1) while containing similar basal levels of cytokines
(Appendix Fig S1) served as the control injectates (designated
Control-TBS). After 48 h (Xu et al, 2016), we immunostained
contralateral hemisphere cryosections for P2ry12 and CD68 as
microglial markers. The contralateral hemisphere was exposed to
equal amounts of oAb as the ipsilateral hemisphere by the i.c.v.
injections (Appendix Fig S2) and was therefore studied to avoid any
confounding tissue injury effects from the ipsilateral injection site.
As described previously (Xu et al, 2016), we performed Z-stack
confocal microscopy in the dentate gyrus (DG), the region with the
most robust EE benefits and strongest morphological responses
toward oAb shown by our previous work, and compressed the
stacking images into one 2D image for comprehensive visualization
of all microglial processes. We quantified microglia for their cell
density (#microglia/mm2), circularity, solidity, %CD68 reactivity
per microglia (defined as the percentile of P2ry12+ pixels of each
microglia that are also CD68+), and #branches per microglia using
ImageJ for unbiased morphometry. In the untreated SH mice
exposed to oAb in vivo, we observed significantly decreased micro-
glial density (vs. Control-TBS injections), increased microglial circu-
larity and solidity, decreased #branches/microglia, and increased %
CD68/microglia, all of which indicate a more inflammatory micro-
glial state (Kettenmann et al, 2011). These results are entirely
consistent with our recent report of i.c.v oAb effects in SH mice (Xu
et al, 2016). In contrast, SH mice fed with isoproterenol for 4–
6 weeks showed significantly lower inflammatory changes in their
microglial morphology on all the aforementioned measurements, as
shown both by the original confocal images and Imaris 3D-recon-
structed individual microglia cells (Fig 1A and C). Indeed, the
microglial morphometry of the isoproterenol-fed SH mice exposed
to oAb yielded similar results to those of plain water-fed EE mice
exposed to oAb (Xu et al, 2016), indicating that isoproterenol treat-
ment has microglial immunosuppressive capacity toward oAb simi-
lar to that of EE. Isoproterenol-fed vs. untreated SH mice showed no
significant differences in microglial morphology after injection of
Control-TBS extracts (Fig 1B and C). Thus, the ADTBS-induced dif-
ferences in microglial morphology described above are associated
with oAb. Images with all channels displayed individually are
included in Appendix Fig S3.
Next, we performed mRNA expression profiling by NanoString
on microglia isolated by gradient fractionation and fluorescent-acti-
vated cell sorting (FACS) after the i.c.v. injection of ADTBS. To
provide a baseline for normalization and cross-comparison with
minimal risk of identifying genes responding to patient-to-patient
differences in the brain extract instead of to oAb, an aliquot of the
same patient’s ADTBS extract immunodepleted (ID) of its Ab by the
4G8 monoclonal antibody was i.c.v. injected into littermate mice
within each study. An Abx-42 ELISA developed in our laboratory
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(Yang et al, 2013) indicated that ID-ADTBS had < 4% of the total
Ab42 in the original ADTBS (Fig EV1) while having no significant
differences in endogenous human cytokines (Appendix Fig S2),
indicating the inflammatory differences we observed are Ab-
induced. The microglia from a 3 mm cubic block of the contralateral
hemisphere directly symmetrical to the ipsilateral injection site were
A
C
B
Figure 1. Isoproterenol treatment successfully neutralizes oAb-induced microglia morphology change in SH mice.
A, B Representative images from SH mice treated with isoproterenol vs. water and injected with ADTBS and control-TBS. When injected with ADTBS, SH mice treated
with isoproterenol have microglia with significantly less inflammatory morphological features comparing to their water control. When injected with control-TBS,
SH mice under both treatments showed minimal microglia inflammatory features. Red: P2ry12; green: CD68; blue: DAPI. Scale bar = 100 lm. Corresponding Imaris
3D-reconstructed images featuring two cells per condition are presented under each panel. The spatial relation between each two cells may be adjusted to fit in
the frame with maximum magnification. Scale bar = 50 lm.
C Quantification analysis of SH microglia morphology under different treatments. In control SH mice, ADTBS caused significant decrease in microglial density;
increase in circularity, solidity, and %CD68; and decrease in branching complexity in comparison with control-TBS (*P < 0.05; **P < 0.01; ****P < 0.0001, N = 6).
Isoproterenol treatment significantly rescued all above-mentioned morphological features (*P < 0.05; **P < 0.01; ****P < 0.0001, N = 6). All quantitative data are
presented as mean  SD. Exact P values are listed in Appendix Table S1. All statistical analysis were performed using multiple t-test (unpaired, do not assume
equal SDs) with Holm-Sidak method to determine significance.
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FACS-isolated 48 h after the i.c.v injections using CD11b+/
CD45Med/Ly6CLo/Ly6GLo as sorting markers, and their RNA samples
were analyzed by NanoString nCounter Mouse-inflammatory (V2)
CodeSet containing 249 inflammatory genes and six housekeeping
genes. Only genes with higher-than-background expression were
included in further analysis. Each individual microglial sample from
the ADTBS-injected group was normalized to the average of the
whole control-injected group (ID-ADTBS) for each of the two treat-
ments (SH water and SH isoproterenol). Ratios were presented in
the heat map after conversion to Log2 format. Positive values (red)
indicate a relative increase in an mRNA due to oAb exposure, while
negative ones (blue) indicate relative suppression by oAb. We found
that untreated SH mice had significantly altered inflammatory gene
mRNA profiles upon oAb exposure, while in striking contrast,
isoproterenol-fed SH mice had a largely unaltered and even slightly
immunosuppressive mRNA profile (Fig 2A), similar to what we
have observed in EE mice maintained on regular drinking water (Xu
et al, 2016). Twenty-nine genes that were significantly altered by
oAb exposure in water-fed SH mice were significantly neutralized
by the isoproterenol feeding (analyzed using the ADTBS/ID-ADTBS
ratio; results after Holm–Sidak correction; Fig 2B). An additional 19
genes showed significant neutralization by isoproterenol only before
the Holm–Sidak correction (Fig 2C). Raw NanoString values prior to
their normalization are found in the Dataset EV1. No significant dif-
ferences were observed between isoproterenol-treated and control
SH mice that had no oAb injection, which is consistent with our
previous observations in the EE vs. SH paradigm (Xu et al, 2016).
In summary, our results so far demonstrate that prolonged oral
exposure to isoproterenol in SH mice can successfully protect
against human oAb-induced microglial inflammation in vivo. The
microglial responses to oAb in isoproterenol-treated SH mice are
more “EE-like”, strongly suggesting that norepinephrine signaling
helps mediate EE’s anti-inflammatory benefit for microglia.
Prolonged oral exposure of EE mice to propranolol significantly
diminishes the protective benefits of EE on microglia
To assess further whether b1/b2AR signaling is required for EE’s
anti-inflammatory benefits, we fed EE mice for 4–6 weeks with
propranolol (0.4 g/l in the drinking water), a non-selective bAR
antagonist shown to block EE’s benefits for neuronal function in
previous work on oAb (Li et al, 2013). No sign of decreased physi-
cal activity, body weight, and food/water intake was observed in
the propranolol-treated EE mice. Similar to the case of isoproterenol
treatment, the exact amount of water consumed by individual
mouse was untraceable which may contribute to some variations
among mice of the same treatment group.
Using the same analytical system as described in the prior
section, we first analyzed microglial morphology from the EE mice
fed propranolol or not and then injected i.c.v. with oAb-rich AD-
TBS. As expected, water-fed EE mice showed prevention of oAb-
induced effects on microglial morphology in the contralateral
hippocampus DG area, as shown both in the original confocal
images and in Imaris 3D-reconstructed microglia cells (Fig 3A and
C), as evidenced by minimal changes in cell density (#microglia/
mm2), circularity, solidity, and branching complexity, as well as a
modest %CD68 increase. In contrast, propranolol-fed EE mice
showed significant morphological changes upon oAb exposure that
were similar to those of SH mice on all of the aforementioned
measures of individual microglial morphology, with decreased
microglial density, increased microglial circularity and solidity,
markedly decreased #branches/microglia, and much more increased
%CD68 than untreated EE mice, again as shown both by the original
confocal images and Imaris 3D-reconstructed microglia cells (Fig 3A
and C). These data show that propranolol-fed EE mice have micro-
glial morphologies corresponding to a more inflammatory state, i.e.,
a more “SH-like” state, upon oAb injection than do water-fed EE
mice. Again, propranolol-treated vs. untreated EE mice showed no
difference in microglia morphology upon injection of Control-TBS
extract (Fig 3B and C), suggesting that the ADTBS-induced
differences in morphology represent a response to oAb. Images
with all channels displayed individually are included in Appendix
Fig S4.
Next, mRNA profiling of FACS-purified microglia after ADTBS
vs. oAb immunodepleted (ID)-TBS injection was performed on the
NanoString nCounter Mouse-inflammatory (V2) CodeSet. The resul-
tant heat map (Fig 4A) includes all genes with higher-than-back-
ground expression and was generated following the same rules as
those in Fig 2A (red indicates relative increase in expression by oAb
over the ID control, while blue indicates relative suppression). Side-
by-side comparison of the propranolol-fed and untreated EE mice
revealed significantly altered inflammatory mRNA profiles upon
oAb exposure by propranolol (Fig 4A). Indeed, 13 genes whose
expression levels were successfully neutralized by EE upon oAb
exposure were now significantly stimulated or suppressed in the
propranolol-treated EE mice (analyzed using ADTBS/ID-ADTBS
ratio; results after Holm–Sidak correction; Fig 4B), suggesting a
more pro-inflammatory expression state. In addition, 19 other genes
also fit into this category before but not after Holm–Sidak correction
(Fig 4C). Raw NanoString values prior to normalization are
included in the Dataset EV2. Like what we observed in isopro-
terenol- vs. water-treated SH mice and in SH vs. EE mice, propra-
nolol alone did not induce any significant microglial inflammatory
gene profile shift.
In summary, propranolol significantly blocked EE’s immunomod-
ulatory benefits to microglia upon oAb exposure, rendering the EE
microglia more “SH-like”. Collectively, our data strongly suggest a
quantitatively important and indispensable involvement of nora-
drenergic signaling in mediating the EE-microglia effects.
In the two NanoString profile studies in SH isoproterenol vs.
water paradigm and EE propranolol vs. water paradigm, we high-
lighted Ccl2, Ccl3, Ccl4, Tnf, and Cxcl10 because they were among
the most significantly altered genes under both paradigms and are
well studied for their biological functions in inflammation, making
them reliable and robust representatives to evaluate microglial
inflammatory status in this and future studies. To confirm their
increase in response to oAb stimulation at the protein level, we
quantified the levels of CCL2, CCL3, CCL4, and CXCL10 in ADTBS-
vs. ID-ADTBS-injected brain tissues by ELISA and observed signifi-
cant increases in all four cytokines upon ADTBS exposure
(Fig EV2). TNFa was not detectable at the protein level with our
1 pg/ml detection limit.
We then attempted to confirm our findings by using a more puri-
fied oAb preparation from human brain that lacks small molecules
(e.g., glutamate and drugs), the brain levels of which could vary
from patient to patient. For this confirmatory step, we adopted a
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Figure 2. Isoproterenol treatment significantly rescues oAb-induced microglial inflammatory gene profile shift in SH mice.
A Heat map of all microglial inflammatory genes with expression level above background cutoff by NanoString nCounter analysis. All data are presented by
Log2 (ADTBS/ID ratio).
B, C Forty-seven genes are significantly rescued by isoproterenol treatment among 140 genes actively expressed by microglia. Twenty-nine of them are significant
(P < 0.01) with Holm–Sidak correction for multi-comparison (B), and 19 of them are significant (P < 0.01) without correction (C). N = 6. All data are presented as
mean  SD. Exact P values are listed in Appendix Table S2.
ª 2018 The Authors EMBO Molecular Medicine e8931 | 2018 5 of 17
Huixin Xu et al EE prevents Ab microgliosis via b-AR EMBO Molecular Medicine
Published online: August 9, 2018 
AC
B
Figure 3. Propranolol treatment significantly diminishes EE’s immunosuppressive effects on microglia against oAb-induced morphology change.
A, B Representative images from EE mice treated with propranolol vs. water and injected with TBS extract from ADTBS and control-TBS. When injected with ADTBS,
EE mice treated with propranolol have microglia with significant inflammatory morphological features, while their water controls showed much more physiological
microglia. When injected with control-TBS, EE mice under both treatments showed minimal microglia inflammatory features. Red: P2ry12; green: CD68; blue: DAPI.
Scale bar = 100 lm. Corresponding Imaris 3D-reconstructed images featuring two cells per condition are presented under each panel. The spatial relation between
each two cells may be adjusted to fit in the frame with maximum magnification. Scale bar = 50 lm.
C Quantification analysis of EE microglia morphology under different treatments. Propranolol-treated EE mice had significantly decreased microglial density,
increased microglia circularity, solidity, and %CD68, while decreased branching complexity after oAb injection comparing to their water-treated controls (*P < 0.05;
**P < 0.01; ***P < 0.001; **** P < 0.0001, N = 6). All quantitative data are presented as mean  SD. Exact P values are listed in Appendix Table S3. All statistical
analysis were performed using multiple t-test (unpaired, do not assume equal SDs) with Holm-Sidak method to determine significance.
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previously published oAb purification protocol that relies on using
size-exclusion chromatography (SEC) to enrich oAb in the “void
volume” fraction during a quantitative removal of small molecules,
followed by 37°C incubation of that fraction to dissociate high MW
Ab oligomers to lower MW oAb comprising dimers and moderately
larger oligomers, which we have found to have particularly high
bioactivity on microglia and neurons in vivo (Yang et al, 2017). To
ensure the injected material had a physiological background, all
incubated oAb-rich solutions were lyophilized and reconstituted in
sterile phosphate-buffered saline (PBS), pH 7.4, before in vivo injec-
tions. The reconstituted samples were quantified using an Abx-42
ELISA. Subsequent adjustment of the reconstitution volume was
done so that each mouse received ~4 pg of human Abx-42 in vivo, a
dose we found to induce significant increases of key cytokines in SH
mice by 24 h after i.c.v. injection. Selective immunodepletion of Ab
successfully removed the bioactivity of this void volume-derived
oAb, rendering it indistinguishable from blank vehicle (PBS;
Fig EV3).
Using this SEC-isolated, low MW Ab oligomer preparation and its
vehicle serving as the negative control, we observed microglial acti-
vation patterns consistent with those obtained from the in vivo stud-
ies of oral isoproterenol or propranolol treatment in SH mice or EE
mice using the whole brain TBS extracts. Specifically, transcript
levels of the five cytokines highlighted by NanoString in both our
prior treatment paradigms (above) were quantified by qPCR. Isopro-
terenol-treated SH mice showed significant prevention of microglial
inflammation upon this SEC-purified oAb injection, whereas propra-
nolol-treated EE mice lost their protection (Fig 5A and B). Note that
with this purified material, we observed much more robust activa-
tion of all five genes than with the unfractionated ADTBS, possibly
due to the enrichment and the reduced influence of other brain-
derived molecules. Further NanoString analysis on those samples
confirmed that the SEC-purified oAb induces consistent gene profile
patterns like ADTBS vs. ID-ADTBS (Fig EV4).
b1/b2AR germline knockout mice fail to gain EE-mediated
protection of microglia against oAb
To confirm the apparently critical role of functional noradrenergic
receptor signaling in mediating the EE effects against microglial oAb
toxicity, we acquired from Jackson Laboratory mice with a germline
global b1/b2AR deletion (homozygous null for both Adrb1 and
Adrb2 genes, referred to here as Adrb1/2KO). The mice were bred
in-house and exposed to EE starting at 4 weeks of age for a total of
4–6 weeks, identical to the EE paradigm we conducted above using
wild-type mice. At the end of EE, the mice were given ADTBS or
control-TBS by i.c.v. microinjection. Brains were harvested and
analyzed for microglial morphology as before.
We observed statistically significant signs of inflammation (de-
creased microglial density, increased circularity/solidity, decreased
branching complexity, and increased CD68+ lysosomal alteration)
upon ADTBS exposure vs. control-TBS in the DG of Adrb1/2KO SH
mice. In stark contrast to our earlier findings in wild-type mice, no
quantifiable difference between SH and EE environments was
observed in Adrb1/2KO mice for all aforementioned morphological
parameters upon in vivo oAb exposure, as shown both by the original
confocal images and by Imaris 3D-reconstructed microglia cells, indi-
cating a complete loss of EE’s protection against microglial inflamma-
tion (Fig 6A and B). Images with all channels displayed individually
are included in Appendix Fig S4. Similar morphological changes were
also observed in CA of hippocampus (Fig EV5), but without obvious
changes in microglial density, which is also consistent with that of
WT SH mice as reported in our previous work (Xu et al, 2016).
Next, we performed i.c.v. injections of the SEC-purified human
brain low MW oAb fractions (vs. PBS) into EE vs. SH Adrb1/2KO
mice and analyzed the expression levels of the top five cytokines
(Ccl2, Ccl3, Ccl4, Cxcl10, and Tnf) by qPCR. oAb now produced
indistinguishable pro-inflammatory responses in both SH and EE KO
mice (Fig 6C). Collectively, the morphometry and expression analy-
ses indicate that the lifelong absence of b1/b2AR leads to almost
complete loss of the beneficial modulation of microglial phenotype
by EE, consistent with our earlier observations in EE mice chroni-
cally treated with propranolol.
Quantification of norepinephrine in mice reveals disrupted NE
signaling in SH but not EE mice
We quantified norepinephrine (NE) in the DG of wild-type mice kept
in SH or EE. Knowledge of NE properties in the mouse dentate gyrus
during EE is lacking. We first measured NE levels in dissected whole
DG tissue. The DG was rapidly dissected on ice and snap-frozen
until analysis by high-performance liquid chromatography with
electrochemical detection (HPLC-ECD). The results showed that
when the mice were injected i.c.v. with the SEC-purified oAb (vs.
PBS), a small (~20%) but highly significant increase in DG NE level
of SH mice was observed at 24 h, whereas no detectable change in
NE occurred in EE mice (Fig 7A).
Next, we sampled interstitial fluid (ISF) from the DG by in vivo
microdialysis to specifically quantify extracellular NE levels. The
mice underwent implantation of a microdialysis guide cannula into
the hippocampal dentate gyrus contralateral to the side of the i.c.v.
injection of purified human oAb or PBS. ISF samples were collected
24 h after injection at 1-h intervals using a push-only system with a
1-mm-long, 6 kDa molecular weight cutoff (MWCO) dialysis
membrane and 1 ll/min perfusion of artificial CSF (Fig 7B). ISF
samples were collected at 4°C and then snap-frozen until later anal-
ysis by HPLC-ECD. The room was kept quiet with minimal activities
during ISF sampling to avoid confounding effects on norepinephrine
production. To minimize any technical differences during microdial-
ysis, each oAb-injected mouse was paired with a PBS-injected
◀ Figure 4. Propranolol treatment significantly diminishes EE’s immunosuppressive effects on microglia against oAb-induced microglial inflammatory geneprofile shift.
A Heat map of all microglial inflammatory genes with expression level above background cutoff by NanoString nCounter analysis. All data are presented by Log2
(ADTBS/ID ratio).
B, C Thirty-two genes are significantly altered by propranolol treatment among 160 genes actively expressed by microglia. Thirteen of them are significant (P < 0.01)
with Holm–Sidak correction for multi-comparison (B), and 19 of them are significant (P < 0.01) without correction (C). N = 6. All data are presented as mean  SD.
Exact P values are listed in Appendix Table S4.
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mouse from the same housing environment (SH or EE), and both
these mice were attached simultaneously to a single shared micro-
dialysis perfusion pump. All oAb-injected mice that had been living
in either SH or EE housing had their NE levels normalized to the
average NE level of all PBS-injected mice from that same housing
state, thereby generating a percentage. Mice with any bleeding
noticeable at the microdialysis surgical site prior to probe insertion
were excluded. Strikingly, we found that, in SH mice, i.c.v. human
oAb induced a significant ~50% decrease in extracellular (ISF) NE
level, but in EE mice, no effect of oAb was observed (Fig 7C).
Furthermore, qPCR analysis of the post-i.c.v. injection contralat-
eral microglia indicates that both b1-AR and b2-AR transcription
levels decreased ~50% in SH mice after oAb injection but did not
change at all in EE mice (Fig 7D). We were able to identify one b2AR
antibody of a specific lot that successfully detects microglial b2AR
despite the very low protein yields. When pooling microglia harvested
from four contralateral brain blocks as described above, we were able
to show that oAb injection caused a complete loss of the b2AR band
by Western blot in SH mice but not in EE mice (Fig 7E; raw blot
images in Appendix Fig S6), confirming our findings at the RNA level.
No b1AR antibody was found to perform under these conditions, but
because of the similarities between b1AR and b2AR, we speculate that
b1AR should follow the same type of change as b2AR.
Collectively, these data point to a substantially disrupted NE
signaling system in SH mice exposed to human oAb, as shown by
increased total tissue [NE] but lowered free extracellular [NE] and
decreased availability of b1/b2AR in the dentate gyrus. In striking
contrast, EE mice maintained stable NE levels in both whole tissue
and ISF and unchanged b1- and b2-AR transcript levels upon oAb
injection, indicating that under environmental enrichment, unal-
tered noradrenergic homeostasis is associated with the prevention
of microglial inflammation.
A
B
Figure 5. SEC-purified AD brain extract can recapitulate the phenotypes observed using straight AD brain extract in SH and EE mice orally treated with
isoproterenol or propranolol.
A In SH mice, five top cytokines highlighted by NanoString screening are significantly increased by injection of SEC separated oAb vs. PBS, measured by qPCR.
Isoproterenol treatment successfully neutralizes such inflammatory responses.
B In EE mice treated with propranolol, the same five top cytokines are significantly increased by injection of SEC separated oAb vs. PBS, measured by qPCR. Control EE
mice showed complete rescue consistent with previous studies.
Data information: All data are presented as mean  SD. *P < 0.01; **P < 0.001; ***P < 0.0001; ****P < 0.00001. N = 6. Exact P values are listed in Appendix Table S5. All
statistical analysis were performed using multiple t-test (unpaired, do not assume equal SDs) with Holm-Sidak method to determine significance.
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Lastly, we tested whether the cAMP/PKA pathway, a common
signaling pathway utilized by b1/b2AR, mediates the downstream
effects. We inhibited cAMP and PKA pathways by one cAMP inhi-
bitor (cAMP-Rp, 50 lM) and two PKA inhibitors (KT5720, 100 nM;
PKA inhibitor fragment (6-22) amide (marked as PI (6-22)),
100 nM) in primary microglia cultures treated with oAb and isopro-
terenol (100 lM). All doses were chosen to be within fivefold of the
compound’s IC50 without any cytotoxicity. The cells were harvested
after 4 h. Because our culturing system (20,000 cells/well in 150 ll
culture media) does not yield sufficient amount of cytokines at
protein level to be detected by ELISA, we analyzed the treated
primary microglia by qPCR for the expression of the five cytokines
highlighted by our previous NanoString analysis (Ccl2, Ccl3, Ccl4,
Cxcl10, and Tnf). We found that 10 pg of oAb induced significant
increases of all five cytokines by 4 h in the primary cultures, and
isoproterenol had significant rescue effects. cAMP-Rp significantly
diminished the anti-inflammatory effects of isoproterenol in Tnf
expression but not as much for the other four cytokines. Both PKA
inhibitors failed to reverse any isoproterenol effects (Fig 7F). The
findings suggest that the downstream signaling of b1/b2AR’s anti-
inflammatory effects on oAb-stimulated microglia is only partially
cAMP-dependent and not PKA-independent.
Discussion
Mounting evidence in humans suggests potential cognitive benefits
detectable in old age of intellectually challenging and physically active
lifestyles. With the widespread availability of disease-modifying drugs
for Alzheimer’s disease still years away, understanding the biological
mechanisms underlying lifestyle benefits could lead to valuable addi-
tional approaches to lessen the global crisis of age-related dementia
and could simultaneously enable discoveries of new pharmacological
targets other than the key pathological proteins currently being
targeted in AD clinical trials. Environmental enrichment is a labora-
tory adaptation to model effects of human lifestyle. It has been studied
in rodent models for its potential benefit in ameliorating neuropatho-
logical features resembling those of AD. We recently documented
potent immunomodulatory effects of EE in protecting microglia from
the early phase of oAb-induced inflammation in vivo, thereby expand-
ing EE’s known benefits from purely neuronal to the realm of innate
immunity (Xu et al, 2016). One other study offered support for EE-
microglia effects by reporting enhanced microglial clearance of Ab
plaques by EE in 5 × FAD mice, revealing another feature of EE’s
modulation of microglia when the cells are chronically exposed to
excessive levels of oAb (Ziegler-Waldkirch et al, 2018).
Pro-inflammatory microglial activities are believed to produce
various detrimental consequences in the brain and help promote
neurodegeneration. One very recent study demonstrated that
inflammatory microglia promote Ab aggregation in vivo by releasing
ASC (apoptosis-associated speck-like protein containing CARD)
specks into extracellular space, offering yet another strong piece of
evidence for the destructive power of microglial inflammation
(Venegas et al, 2017). The recent identification of microglial gene
variants contributing to late-onset AD in a GWAS study of 85,000+
subjects further highlighted the importance of microglia in AD
pathogenesis (Sims et al, 2017). The molecular mechanisms driving
EE’s immunomodulation of microglia, once identified, could inform
the development of synergistic behavioral and pharmacological
approaches to downregulate microglial inflammation and neutralize
its damage, but, until the current study, the responsible biological
mechanism remained known.
Here, we have identified b-adrenergic signaling as the apparent
key mediator of EE’s highly consistent benefit of preventing oAb-
induced microglial inflammation in the living brain. Our findings
from a combined comparison of housing paradigms and pharmaco-
logical treatments indicate that prolonged daily exposure to isopro-
terenol successfully prevented SH mice from developing microglial
inflammation upon exposure of oAb, while prolonged exposure of
EE mice to propranolol significantly diminished EE’s protective
effects and allowed much greater microglial inflammation from oAb
even though the EE mice treated with propranolol still maintained
their daily activity and had a body habitus indistinguishable from
their untreated littermates. These data clearly demonstrate that a
very substantial part of EE’s immunosuppression on microglia is
driven via b1/b2AR signaling. Blocking b1/b2AR signaling
prevented acquisition of microglial immuno-protection. None of our
drug treatments or the EE paradigm alone induced any significant
microglial inflammatory gene profile changes when oAb was not
present, indicating that the regulation of microglia via b1/b2AR
signaling is more relevant to microglial inflammatory status than to
physiological status. Importantly, these pharmacological results
were confirmed through genetic manipulation when we observed a
consistent loss of EE benefits on oAb-exposed microglia in mice
completely lacking functional b1/b2ARs. While a microglia-specific
Adrb KO mouse line is not yet available, the recently identified
microglia-specific marker, Sall1, and the successful downregulation
of other microglial genes via Sall1-Cre (Buttgereit et al, 2016) indi-
cate that future research could potentially develop mice with selec-
tive deletion of microglial b-ARs in order to further dissect the
functions of b-adrenergic signaling in the EE-mediated downregula-
tion of microglial inflammation.
◀ Figure 6. Germline knockout of b1 and b2AR (Adrb1/2 KO) leads to loss of EE protection on microglia with acute oAb exposure.A Representative images from SH and EE Adrb1/2KO mice injected with ADTBS and control-TBS. When injected with ADTBS, both SH and EE mice have microglia with
significant inflammatory morphological features in DG and CA. When injected with control-TBS, both SH and EE mice showed minimal microglia inflammatory
features. Red: P2ry12; green: CD68; blue: DAPI. Scale bar = 100 lm. Corresponding Imaris 3D-reconstructed images featuring two cells per condition are presented
under each panel. The spatial relation between each two cells may be adjusted to fit in the frame with maximum magnification. Scale bar = 50 lm.
B Quantification analysis of microglia morphology in DG. Both SH and EE Adrb1/2KO mice had significantly decreased microglial density, increased microglia circularity,
solidity, and %CD68, while decreased branching complexity after oAb injection comparing to their controls (*P < 0.05; **P < 0.01; ***P < 0.001, N = 5). Exact
P values are listed in Appendix Table S6.
C qPCR analysis of SH and EE Adrb1/2KO mice microglia after i.c.v. injection of SEC separated oAb vs. PBS. Both SH and EE mice showed increase in cytokine expression
with oAb injection. N = 4. No significant difference between SH and EE is observed.
Data information: All quantitative data are presented as mean  SD. All statistical analysis were performed using multiple t-test (unpaired, do not assume equal SDs)
with Holm-Sidak method to determine significance.
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Next, we complemented these mechanistic findings by quantify-
ing brain and ISF NE levels. Direct quantification of NE in whole DG
tissue showed a small but significant increase in [NE] in SH mice
upon exposure to oAb. In contrast, microdialysis via a short probe
embedded within the DG revealed that ISF NE levels, which repre-
sent the portion of total NE with impact on biological signaling,
dropped by 50% in SH mice in response to oAb. The increase in
tissue NE and decrease in free extracellular NE in DG together point
A
D
F
E
B C
Figure 7. Direct quantification of norepinephrine (NE) showed disrupted NE homeostasis by oAb in SH mice but not in EE mice.
A Whole tissue NE quantification of the DG shows significant increase in NE level in SH mice injected with oAb vs. PBS. EE mice showed minimal change in DG tissue
NE level with oAb injection vs. PBS. *P = 0.0083, N = 6.
B Illustration for in vivo microdialysis from contralateral DG after i.c.v. injection. The brain images are adopted from Paxinos and Franklin (2012).
C Quantification of NE in the ISF collected by in vivo microdialysis shows significant decrease in extracellular NE in the DG of SH mice with i.c.v. injection of oAb vs.
PBS, while EE mice showed minimal change. *P < 0.01 (P = 0.0060), N = 6.
D qPCR analysis of microglial Adrb1 and Adrb2 RNA level showed significant decrease in both Adrb1 and Adrb2 transcription in SH mice after oAb injection. EE fully
rescued the phenotype. ***P < 0.0001 (Adrb1 P = 4.1E-05; Adrb2 P = 8.7E-07). N = 6.
E Western blots of b2AR in SH and EE mice +/ oAb injection. Each sample contained microglia isolated from four mice following the same protocol as that of
NanoString analysis.
F qPCR analysis of primary microglia culture treated with oAb, isoproterenol, cAMP-Rp, KT5720, and PKA inhibitor fragment (6-22) amides (PI (6-22)) showed significant
increase in cytokine expression by oAb and robust rescue effects by isoproterenol. cAMP-Rp reversed isoproterenol protection in Tnf but not others. Both KT5720 and
PKA inhibitor fragment (6-22) amides did not affect isoproterenol. *P < 0.05, **P < 0.01. N = 8. Exact P values are listed in Appendix Table S7.
Data information: All quantitative data are presented as mean  SD. All statistical analysis were performed using multiple t-test (unpaired, do not assume equal SDs)
with Holm-Sidak method to determine significance.
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to oAb-impaired NE regulatory machinery in SH mice, a phenotype
that was again successfully neutralized by EE. Besides reduced NE
availability, we also observed strong decreases in the transcription
levels of both adrenergic receptors and the protein level of b2AR
from oAb in SH mice, whereas minimal and insignificant changes
occurred in EE mice. A decrease in the mRNA level of both these
receptors has been reported in microglia stimulated with LPS
(Gyoneva & Traynelis, 2013), connecting a pro-inflammatory state
to the decrease in microglial b1/b2AR expression. Taken together,
our data demonstrate for the first time that EE has a direct impact
on the NE dynamics in hippocampal tissue and that EE suppresses
excessive microglial inflammation in the early phase of oAb expo-
sure by maintaining the strength of b-adrenergic signaling in micro-
glia. We speculate that oAb toxicity may impair the NE release/
reuptake machinery in SH mice, leading to increased trapping of NE
inside cells and a significant decrease in the adjacent extracellular
space, and hence a loss of anti-inflammatory NE signal. The distur-
bance of NE homeostasis, together with a lowered b-AR level which
exacerbates the loss of NE signal for microglia, renders the micro-
environment in the SH hippocampus exposed to oAb as pro-inflam-
matory. Whether the loss of b1/b2AR is a result of disrupted
membrane receptor recycling could not be determined due to techni-
cal limitations in antibody sensitivity and protein amounts.
However, our previous study in neurons successfully demonstrated
increased b2AR internalization induced by oAb (Li et al, 2013),
suggesting it is possible that in microglia the dynamics of b1/b2AR
follows the same pattern.
In this work, we solely used oAb isolated directly from human
(AD) brain tissue. Various sources of Ab oligomers have been used
in past studies, the vast majority of them being synthetic. Whether
synthetic oAb assemblies faithfully represent the pathological
protein conformers accumulating in the human disease is major
concern. Saline extracts of brain tissues from confirmed AD patients
provide the most clinically relevant source of Ab oligomers. More-
over, human oAb is highly bioactive, perhaps ~100-fold more so
than synthetic oAb preps such as ADDLs when tested side-by-side
on wild-type differentiated rat neurons (Jin et al, 2011). When
administered i.c.v at picomolar doses to wild-type mice, oAb-rich
AD brain extracts provide the most disease-relevant model for the
early oAb toxicity encountered near the onset of the AD process.
Using wild-type mice avoids confounding developmental issues
from overexpression of pathogenic Ab from embryonic stages on, as
seen in APP transgenic mouse lines, and may serve as better models
of the earliest features of sporadic human AD, providing more trans-
lational relevance to early disease mechanisms in humans than do
APP-overexpressing transgenic models. Further, we adapted a previ-
ously published SEC purification protocol (Yang et al, 2017) to
produce much purer oAb solutions that were quantified, lyophi-
lized, and reconstituted in a buffer of choice to the desired concen-
tration for in vivo studies. Using this highly enriched and cleaner
preparation, we could reproduce the same phenomena we had
observed with cruder ADTBS extracts using different brains, with
the quantitative differences among treatment groups accentuated.
We believe this approach has facilitated consistent preparations and
usage of endogenous human oAb for future research here and else-
where.
Propranolol has long been used in the clinic for medical condi-
tions such as high blood pressure, certain arrhythmias, and even
stage fright. A few reports have suggested that b2AR activation can
increase Ab and tau pathology via regulating the internalization of
surface APP molecules and/or c-secretase activity, thereby increas-
ing Ab production, leading to a recommendation of using b-
blockers such as propranolol in the clinical management of AD (Ni
et al, 2006; Dobarro et al, 2013; Wang et al, 2013). However, more
recent studies suggest that b-adrenergic signaling is instead protec-
tive (Heneka et al, 2010; Branca et al, 2014; Liu et al, 2015). The
fact that locus coeruleus (LC) neurons develop tangles and die out
in AD, leading to reduced NE signaling in humans (Matthews et al,
2002), is potentially relevant to our work. Indeed, lesioning LC in
mice and rats increases Ab cytopathology (Kalinin et al, 2007;
Heneka et al, 2010; Jardanhazi-Kurutz et al, 2011). Moreover, one
b1AR agonist was recently found to decrease overall brain
inflammation and lessen AD pathology in an aggressive AD mouse
model (Ardestani et al, 2017), providing strong support that b-
adrenergic signaling plays a positive role in helping control AD-
related brain injury. In addition to those studies utilizing exoge-
nous agonist to the NE signaling, our discovery emphasizes that
EE provides anti-inflammatory protection on microglia via endoge-
nously enhanced b-adrenergic signaling independent of any phar-
macological manipulation. The long established comprehensive
benefits of EE to brain health, both in laboratory models and in
human studies, strongly support the positive role of b-adrenergic
signaling. In combination with earlier reports of decreased NE
signaling in AD brain, our study highlights the potential impor-
tance of avoiding chronic beta-blockers in MCI and AD subjects. In
this regard, a recent study conducted in > 10,000 nursing home
denizens showed a strong correlation between usage of b-blockers
and functional decline, and this negative effect was more obvious
in residents with moderate or severe cognitive deficits (Steinman
et al, 2017).
On the other hand, any potential benefit of long-term b-agonist
usage (e.g., in treating asthma) for cognitive function in the elderly
is not well documented. A recent epidemiology study identified b-
agonist usage as a protective factor against Parkinson’s disease
(Mittal et al, 2017). Similar studies that focus on AD and dementia
would be of great value, for although active lifestyle and constant
intellectual challenge are highly recommended in the middle-aged
and elderly populations to potentially lessen AD and dementia, in
practice, such prolonged behavioral modification will not be accessi-
ble to all for physical and economic reasons. Our study identifies b-
adrenergic signaling as the principal cellular event that is chroni-
cally enhanced by an enriched environment to prevent aberrant
microglial inflammation occurring from oAb in AD. Further clinical
investigation and epidemiological studies of people who are
prescribed b-agonists for chronic use could indicate whether such
treatment leads to lower incidence and less rapid progression of
mild cognitive impairment (MCI) or AD symptoms. Although a life-
style modification approach has many superior aspects over phar-
macological agents both physiologically and financially, such
studies could be important for paving the road toward developing a
safe b-agonist as a therapeutic for AD when lifestyle enrichment is
not possible for certain patients.
In summary, our multifaceted findings reveal that b-adrenergic
signaling is a major, if not dominant, mediator of the immunosup-
pressive effects of EE on oAb-induced microglial inflammation.
Moreover, we establish here a model for systematically investigating
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signaling pathways and their functions on microglia in AD—using
human brain-derived oAb on non-genetically manipulated, wild-
type mice. Our identification of NE signaling as a principal mediator
between EE and microglia suggests that increased neuronal activity
from EE stimulation may modulate microglial behavior through
interactions of neurotransmitters with their cognate receptors
expressed on microglia, providing evidence that CNS neurotransmit-
ters can modulate not just neurons but also innate immune cells.
NE signaling was previously identified as a major mediator of EE’s
protection of neuronal function following human oAb exposure (Li
et al, 2013). Our data suggest the existence of common cellular
events triggered by EE that benefit both neurons and microglia via
the same signaling pathway but with different manifestations. The
beneficial role of enhanced b-adrenergic signaling identified here
could apply to other neurological diseases, providing new insights
into the biological underpinnings of EE and how to maximize its
benefits for the brain.
Materials and Methods
Animals
The Harvard Medical School Standard Committee on Animals and
BWH IACUC approved all experiments involving mice in this study.
All mice were male. Animals were housed in a temperature-
controlled room on a 12-h light/12-h dark cycle and had free access
to food and water. BL6/129 mice were purchased from Taconic.
Mice with germline Adrb1/2 knockout were purchased from Jack-
son Laboratory (Stock No: 003810) and bred in-house. All mice used
in the experiments were 8- to 10-weeks old.
Antibodies
The following antibodies were used for this study: P2ry12 (1:500), a
generous gift from Dr. Oleg Butovsky; CD68 (1:200), Abcam
ab53444, RRID:AB_869007; 4G8 (20 lg/reaction), Biolegend RRID:
AB_10175149; Anti-CD11b (1:100), BD Biosciences Cat# 552850
RRID:AB_394491; anti-CD45 (1:200), eBioscience Cat# 17-0451-82
162 RRID:AB_469392; anti-Ly6C (1:400), eBioscience Cat# 12-5932-
82 RRID:AB_10804510; anti-Ly6G (1:100), Biolegend 163 Cat#
127605 RRID: AB_1236488; GAPDH (1:5,000), Sigma-Aldrich G9545
RRID: AB 796208; b2AR (1:500), Abcam ab182136 (lot: GR302897-
20) RRID: AB not available.
Detailed methods regarding environmental enrichment setup,
mouse brain tissue staining and microglial morphology analysis,
microglia isolation and RNA analysis, and human brain extract
preparation and analysis are reported by previous publications
(Yang et al, 2013, 2017; Xu et al, 2016). Methods unique to this
study are listed below:
Oral administration of propranolol and isoproterenol
Mice were orally exposed to isoproterenol or propranolol through
the daily drinking water for 4–6 weeks. Isoproterenol was adminis-
tered at 0.1 g/l, and propranolol was administered at 0.4 g/l.
Colored, light-proof water bottles were used in all groups. Total
water consumption of each cage was recorded. Note that the water
consumption of individual animals cannot be determined and there-
fore may add variation to the study.
Mouse cytokine quantification at protein level
Mice were injected i.c.v. with ADTBS or ID-ADTBS. The brain
tissue was harvested following the same method as that for Nano-
String analysis. The brain blocks were homogenized in TBS with
protease inhibitor at 1:2 ratio (1 mg wet tissue: 2 ml homogeniza-
tion buffer). The brain TBS homogenates were centrifuged at
50,000 g for 1 h at 4 degree to remove all non-water-soluble frac-
tions. The supernatant fractions were analyzed by mouse cytokine
ELISA kit from Meso Scale Discovery (K15069L). For each sample,
the loading volume was adjusted based on total protein concentra-
tion determined by BCA protein assay so each ELISA reaction
received same amount of total protein.
Human cytokines quantification
All human brain extracts were analyzed by LEGNEDplexTM Human
Inflammation Panel to cover major cytokines that may be present in
human brains.
Stereotactic intracerebroventricular (i.c.v.) injection
The lateral ventricle was located by stereotactic coordinates of
bregma2.5 mm, midline+3.1 mm, and dura3.7 mm in wild-type
mice, and bregma2.4 mm, midline+3.0 mm, and dura2.7 mm in
Adrb1/2 KO mice. Through a Hamilton syringe (25 ll) in a stereo-
tactic holder, 4 ll of injectate was slowly delivered over 5 min.
When this was combined with microdialysis, the ventricle coordi-
nates were changed to bregma2.5 mm, midline3.1 mm, and
dura3.7 mm in wild-type mice to accommodate the microdialysis
probe placement.
Microscopy and image analysis
All images were acquired by Zeiss LSM710 confocal microscope
using 20× objective. A Z-stack was collected for each field of view to
capture all details in microglial processes. Microglia morphological
features were quantified by ImageJ particle analysis and Skeleton
analysis. Imaris reconstruction was performed using Imaris software
with the same Z-stacks.
In vivo microdialysis
These mice had an intracerebral guide cannula implanted using
coordinates for right hippocampal dentate gyrus placement
(bregma1.9 mm, midline1.1 mm, and dura1.5 mm). After
inserting probes with 6 kDa molecular weight cutoff (MWCO)
membranes (CMA), artificial CSF (in mM: 1.3 CaCl2, 1.2 MgSO4, 3
KCl, 0.4 KH2PO4, 25 NaHCO3, and 122 NaCl, pH 7.35, filtered and
degassed) was perfused at flow rates 1.0 ll/min with an infusion
syringe pump (Stoelting). Microdialysates were collected in a frac-
tion collector at 4°C every hour. Mice were housed in a Raturn cage
system (Bioanalytical Systems), which allowed normal movements
and activity. All ISF samples were snap-frozen and stored at 80°C
until further analysis.
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Quantification of norepinephrine
All mouse brain samples were snap-frozen upon dissection and
analyzed at the Neurochemistry Core Facility at Vanderbilt Univer-
sity by Dr. Ginger Milne. All interstitial fluid (ISF) samples from
in vivo microdialysis were analyzed at the Center for Translational
Neuromedicine (University of Copenhagen, Denmark) by Dr. Pia
Weikop. All the ISF samples were processed on Prodigy 3 lm ODS-
3 C18 column (2 mm × 100 mm, particle size 3 lm, Phenomenex).
The mobile phase consisted of 55 mM sodium acetate, 1 mM
octanesulfonic acid, 0.1 mM Na2EDTA, and 8% acetonitrile,
adjusted to pH 3.2 with 0.1 M acetic acid, and was degassed using
an online degasser. Seven ll of the samples was injected, and the
flow rate was 0.15 ml/min. Electrochemical detection was accom-
plished using an amperometric detector (Antec Decade, Antec,
Leiden, NL) with a glassy carbon electrode set at 0.8 V, with a Ag/
AgCl electrode as reference electrode. The output was recorded on a
computer program LC Solution from Shimadzu, which was also
used to calculate the peak areas.
Western blot of microglial b2AR
Brain microglia were purified as described by Xu et al (2016).
Microglia from four mice were pooled and lysed in 40 ll of RIPA
lysis buffer and treated for 30 min at 37°C with 2 units of DNase
(TURBO, Invitrogen AM2239) to remove DNA released during
lysing. The samples were then mixed with 4X SDS and incubated
at room temperature for 10 min and boiled at 65°C for 5 min.
The Western blots were developed using PierceTM Fast Western
Blot Kits, SuperSignalTM West Femto. GAPDH was used as loading
control.
Preparation of primary microglia and treatment
Primary microglia cultures were prepared from P0 mouse pups
following a published protocol (Lian et al, 2016). Briefly, the
cortices of the brains were harvested and digested by trypsin. The
cells were plated in poly-D-lysine (PDL)-coated T-75 flasks as mixed
glial cultures and let grow till confluent astrocyte layers form. The
microglia were isolated by tapping the flasks vigorously. Purified
microglia were seeded into PDL-coated 96-well plates at
20,000 cells/well density and let recover overnight. The cells were
treated with 10 pg of SEC-purified oAb, 100 lM isoproterenol,
50 lM cAMP-Rp (Tocris 1337), 100 nM KT5720 (Tocris 1288), and
100 nM PKA inhibitor fragment (6-22) amide (Tocris 1904). Cells
were harvested after 4 h of incubation at 37°C and lysed for RNA
analysis.
Statistical analysis and heat maps
All quantification results were analyzed using multiple t-test (un-
paired, do not assume equal SDs). Statistical significance was deter-
mined using the Holm–Sidak method, with alpha = 0.05. All data
were analyzed by Shapiro–Wilk test first to determine normality (all
passed). N indicates total number of mice under each condition.
The sample sizes were determined by power analysis based on pre-
specified effect and variation estimated from preliminary studies.
Each experiment included animals from two or more independent
cohorts to eliminate cohort-specific bias. The initial sample sizes
were larger than calculated to compensate for any possible exclu-
sion of data points, which was minimal. Any animal with significant
bleeding during/after surgery was excluded from the study to avoid
confounding from excessive tissue injury. For all experiments, the
animals were assigned to different groups by random selection and
the animal caregiver was not the investigator. Sample processing
and data analysis were carried out by investigators blinded to the
intervention. Heat maps were generated using the heatmap.2 func-
tion in the gplots package in R.
Expanded View for this article is available online.
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The paper explained
Problem
Alzheimer’s disease (AD) is affecting a rapidly growing population
globally. A pharmacological solution still faces multiple challenges,
but lifelong experiences such as education, challenging occupation,
exercise, and socialization are shown to provide protection against
the development of AD later in life. Environmental enrichment (EE), a
laboratory model to study such lifestyle benefits, has extensive anti-
inflammatory effects on brain microglia whose malfunction under
amyloid-b (Ab) challenge is tightly connected to the progression of AD
both in animal models and human subjects. Identifying the molecular
mechanisms that drive EE’s protective effects on microglia against Ab
is critical for offering new insights into therapeutic development and
gaining knowledge on the communication and regulation between
the environment and brain innate immune system to benefit future
research on brain health.
Results
Here, we provide evidence that enhanced b-adrenergic signaling is
the key behind EE’s anti-inflammatory benefits on microglia under Ab
assault. We show that oral treatment of b-adrenergic receptor (b-AR)
agonist mimics EE’s benefits on microglia in mice housed in standard
housing (SH), while oral treatment of b-AR antagonist to environmen-
tal enriched mice diminished EE’s protection. Genetically removing b-
AR also blocks the mice from gaining microglial benefits from EE.
Further, we demonstrate that SH mice experienced disrupted b-adre-
nergic signaling with Ab exposure shown by decreased extracellular
norepinephrine and decreased level of microglial b-AR. EE maintains
the b-adrenergic signaling strength in mice with Ab exposure, there-
fore keeping brain microglia at a less inflammatory state.
Impact
The identification of b-adrenergic pathway activation as one major
molecular event mediating EE’s effects on microglia connects outside
environment to brain innate immune system by neurotransmitter
signaling. The finding might open up new research into the neuro-
microglia communication via neurotransmitters and have clinical
implications regarding usage of b-agonists and b-antagonists to treat
other diseases and their potential cognitive impact in the population
vulnerable to AD. Further research might decide whether the same
mechanism can benefit other neurological disorders where aberrantly
activated microglia play pivotal roles in disease progression.
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